Toxic metabolites, identifying

Small-scale in vitro test systems may now be employed to assess biopharmaceutical properties or the drug s potential behaviour after in vivo administration. For example, drug penetration through monolayers of epithelial cells in tissue culture can be used to examine bioavailability. The drug s metabolism can be studied in vitro using hepatic microsomes and potentially toxic metabolites identified before problems arise in vivo Although not absolute, these tests... 

Mefenamic is a nonsteroidal anti-inflammatory drug used to treat pain, including menstrual pain. Hata et al. [11] treated that drug with P. sordida, and obtained a 90% reduction in mefenamic acid concentration (initial concentration 24 mg L ) after 6 days. The system produced four metabolites, identified as 3 -hydroxymethyl-mefenamic acid, 3 -hydroxymethyl-5-hydroxymefenamic acid, 3 -hydroxmethyl-6 -hydroxymefenamic acid, and 3 -carboxymefenamic acid. Moreover, the authors confirmed that the fungus almost completely removed the acute lethal toxicity of mefenamic towards the freshwater crustacean Thamnocephalus platyurus after 6 days of treatment, suggesting that the metabolites are less toxic than the parental compound. 

Comparative Toxicokinetics. Metabolic pathways and mechanisms of hepatotoxicity of carbon tetrachloride have been the subject of many studies in intact animals and in vitro, and are therefore better understood than for many other chemicals. However, there are apparently no data on metabolism of carbon tetrachloride in humans. It would be valuable to conduct in vitro experiments with human liver samples and hepatocytes to determine whether metabolic pathways and toxic metabolites are similar to those found in animals. It would also be beneficial to identify an animal model in which MFO systems develop in uteroas they do in the human fetus. 

Toxicity is a major cause for the withdrawal of drugs from the market and it is a major concern for pharmaceutical researchers. Reactive metabolism is certainly a very hot topic within the whole approach to drug metabolism. The downstream consequences of not identifying reactive metabolites may be financially catastrophic. There is an increasing drive to have early prediction of the metabolic fate and interactions of candidate drug molecules. Factors such as metabolic stability, toxic metabolite production, and P450 inhibition and induction are all routinely monitored to prevent compounds with poor pharmacokinetic properties from progressing forward onto clinical trials. 

Whole-body distribution studies are essential for classical small-molecule drugs in order to exclude any tissue accumulation of potentially toxic metabolites. This problem does not exist for protein drugs, where the catabolic degradation products (amino acids) are recycled in the endogenous amino acid pool. Therefore, biodistribution studies for peptides and proteins are performed primarily to assess targeting to specific tissues as well as to identify the major ehmination organs [4]. 

However we also know that the test systems are not infallible they are subject to false positive outcomes (i.e., a false alert) or false negative outcomes (missing a human toxicity raises concern for all stakeholders). False positive outcomes may be the result of several factors, including occurrence of toxicity only at exaggerated dose levels (identifiable by determining safety margins based on comparative plasma exposure, or including biomarkers if available), or species-specific effects or toxic metabolites (as shown to not occur in humans). The consequence... 

Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been made for 2-butoxyethanol. Insufficient data were available to estimate MRLs for 2-butoxyethanol acetate. Since 2-butoxyethanol acetate is metabolized to the same toxic metabolite as is 2-butoxyethanol, it seems likely that the MRLs for 2-butoxyethanol acetate would be similar to those of 2-butoxyethanol. An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure. 

As the compound reaches the late discovery and candidate selection stage, the focus is to determine its major metabolic pathways, metabolic difference between species, and to identify potential pharmacologically active or toxic metabolites. Because of the complexity, comprehensive metabolite characterization studies have been typically conducted at this stage with radiolabeled standard. Identification of circulating metabolites is also important at this stage to explain the pharmacokinetic or the pharmacodynamic profile. An NCE may show efficacy that is inconsistent with what is predicted based upon the known concentration of the parent drug. These inconsistencies could be due to the presence of active metabolites. The knowledge of these metabolites will also dictate how the analysis of samples will be conducted in the development and clinical studies. 

The feature of all inherited disorders is a genetic defect, often the result of a single base substitution or deletion in the DNA. which results in the reduced synthesis of a particular protein or in the synthesis of a protein with an altered amino acid coniposiiion. A classical inborn error of metaholisni involves a missing or defective en/yme which causes a block on a metabolic pathway and the production of toxic metabolites. More than four thousand disorders involving single genes have been identified. 

---